Aficamten Compared to Placebo in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy

What is the Purpose of this Study?

The purpose of this study is to compare the effects of an experimental drug called aficamten and placebo (inactive substance) on the exercise capacity and health status of patients with symptomatic, non-obstructive hypertrophic cardiomyopathy (nHCM). nHCM is typically a genetic condition in which the main pumping chamber of the heart (left ventricle) becomes abnormally thickened and stiff. The effectiveness of aficamten and placebo will be compared by measuring patients’ ability to exercise, heart failure symptoms, and structure of the heart, as well as questionnaires regarding the status of general health, nHCM symptoms, and quality of life. The safety and tolerability of aficamten at increasing dose levels will also be studied. All participants will eventually be eligible to receive the study drug.


Eligibility

  • * Between 18-85 years of age
  • * Body mass index \< 40 kg/m2
  • * Diagnosed with nHCM and has a screening echocardiogram with the following:
Show more

Where can I participate?

Beverly

More about this Clinical Trial

What is the full name of this clinical trial?

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Study Details
Disease Type/Condition

Other

Principal Investigator

Rader, Florian

Age Group

Adult

Phase

III

IRB Number

STUDY00002841

ClinicalTrials.gov ID

NCT06081894

Key Eligibility
ClinicalTrials.gov

How do I learn more about this study?
Email
clinicaltrials@cshs.org
Study Detail
Disease Type/Condition

Other

Principal Investigator

Rader, Florian

Age Group

Adult

Phase

III

IRB Number

CY6033

ClinicalTrials.gov ID

NCT06081894

Key Eligibility
ClinicalTrials.gov

Contact
Email
clinicaltrials@cshs.org